Furthermore, trastuzumab stimulates antibody-dependent cellular cytotoxicity (ADCC) by binding to HER2 on tumor cells and activating immune effector cells, primarily natural killer (NK) cells, through Fc region interactions. The gene discussed is ERBB2; the disease is neoplasm.